SunTrust Banks, Inc. reiterated their buy rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research report released on Friday. The brokerage currently has a $160.00 price objective on the biopharmaceutical company’s stock. SunTrust Banks also issued estimates for TESARO’s Q4 2017 earnings at ($2.41) EPS, FY2017 earnings at ($8.23) EPS, Q1 2018 earnings at ($2.11) EPS, Q2 2018 earnings at ($1.84) EPS, Q3 2018 earnings at ($1.94) EPS, Q4 2018 earnings at ($1.64) EPS, FY2018 earnings at ($7.52) EPS, FY2019 earnings at ($4.56) EPS, FY2020 earnings at $1.69 EPS and FY2021 earnings at $7.48 EPS.
Several other research firms also recently issued reports on TSRO. Robert W. Baird reaffirmed a neutral rating and set a $125.00 price target on shares of TESARO in a research note on Monday, October 2nd. Janney Montgomery Scott reaffirmed a neutral rating on shares of TESARO in a research note on Friday, July 14th. Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the company a buy rating in a research note on Wednesday, July 19th. Cann reaffirmed a buy rating and set a $199.00 price target on shares of TESARO in a research note on Friday, September 8th. Finally, ValuEngine raised shares of TESARO from a sell rating to a hold rating in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Hold and an average price target of $161.72.
TESARO (NASDAQ:TSRO) traded up $0.08 during mid-day trading on Friday, hitting $91.09. 1,062,200 shares of the stock traded hands, compared to its average volume of 1,028,935. TESARO has a 12-month low of $89.00 and a 12-month high of $192.94. The company has a quick ratio of 5.41, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.72) earnings per share. research analysts predict that TESARO will post -8.21 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Given “Buy” Rating at SunTrust Banks, Inc.” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/11/tesaro-inc-tsro-given-buy-rating-at-suntrust-banks-inc.html.
In other news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders sold 35,692 shares of company stock valued at $4,628,976 over the last 90 days. Corporate insiders own 40.50% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Exane Derivatives acquired a new position in shares of TESARO during the third quarter valued at about $106,000. Botty Investors LLC acquired a new position in shares of TESARO during the second quarter valued at about $140,000. Nordea Investment Management AB acquired a new position in shares of TESARO during the second quarter valued at about $167,000. Oppenheimer Asset Management Inc. grew its holdings in shares of TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of TESARO by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.